Photo of Cary O. Harding, M.D.

Cary O. Harding M.D.

  • (503) 494-8307
    • Professor of Molecular and Medical Genetics School of Medicine
    • Molecular and Medical Genetics Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Harding received his medical degree in 1987 from the University of Washington School of Medicine in Seattle. He completed his pediatrics residency and fellowship in molecular and medical genetics and pediatrics at the University of Wisconson in Madison. Dr. Harding is fluent in German.

  • Residency:

    • University of Wisconsin Hospital, Madison
  • Fellowship:

    • Fellowship in molecular and medical genetics and pediatrics, University of Wisconsin
  • Certifications:

    • National Board of Medical Examiners, 1988

Publications

  • "Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders." Molecular Genetics and Metabolism  In: , Vol. 125, No. 3, 01.11.2018, p. 251-257.
  • "Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice." Journal of Inherited Metabolic Disease  In: , 08.03.2018, p. 1-10.
  • "Biochemical markers and neuropsychological functioning in distal urea cycle disorders." Journal of Inherited Metabolic Disease  In: , 08.02.2018, p. 1-11.
  • "Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice." Molecular Genetics and Metabolism  In: , Vol. 123, No. 1, 01.01.2018, p. 6-20.
  • "Pegvaliase for the treatment of phenylketonuria : A pivotal, double-blind randomized discontinuation Phase 3 clinical trial." Molecular Genetics and Metabolism  In: , 01.01.2018.
  • "Pegvaliase for the treatment of phenylketonuria : Results of a long-term phase 3 clinical trial program (PRISM)." Molecular Genetics and Metabolism  In: , 01.01.2018.
  • "Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials." EBioMedicine  In: , 01.01.2018.
  • "Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria." Genetics in Medicine  In: , 01.01.2018.
  • "Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders : a double blinded, randomized controlled trial." Journal of Inherited Metabolic Disease  In: , 04.09.2017, p. 1-13.
  • "Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease." American Journal of Medical Genetics, Part A  In: , Vol. 173, No. 9, 01.09.2017, p. 2500-2504.
  • "Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter." Molecular Therapy - Nucleic Acids  In: , Vol. 7, 01.06.2017, p. 339-349.
  • "Fatty acid β-oxidation defects."   Metabolic Diseases: Foundations of Clinical Management, Genetics, and Pathology. IOS Press, 2017. p. 155-189.
  • "Gene and cell therapy for inborn errors of metabolism."   Inherited Metabolic Diseases: A Clinical Approach. Springer Berlin Heidelberg, 2017. p. 155-171.
  • "Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years." Molecular Genetics and Metabolism  In: , 2017.
  • "Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders : Long-Term Follow-up of 21 Cases." Ophthalmology  In: , Vol. 123, No. 10, 01.10.2016, p. 2183-2195.
  • "Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1." Science Translational Medicine  In: , Vol. 8, No. 349, 349ra99, 27.07.2016.
  • "Spectrum of ocular manifestations in cobalamin C and cobalamin A types of methylmalonic acidemia." Ophthalmic Genetics  In: , 16.03.2016, p. 1-11.
  • "Patients' ratings of genetic conditions validate a taxonomy to simplify decisions about preconception carrier screening via genome sequencing." American Journal of Medical Genetics, Part A  In: , Vol. 170, No. 3, 01.03.2016, p. 574-582.
  • "Generating a taxonomy for genetic conditions relevant to reproductive planning." American Journal of Medical Genetics, Part A  In: , Vol. 170, No. 3, 01.03.2016, p. 565-573.
  • "Normal vitamin D levels and bone mineral density among children with inborn errors of metabolism consuming medical food-based diets." Nutrition Research  In: , Vol. 36, No. 1, 01.01.2016, p. 101-108.
  • "High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU)." Molecular Genetics and Metabolism  In: , Vol. 117, No. 1, 01.01.2016, p. 5-11.
  • "Glutamine and hyperammonemic crises in patients with urea cycle disorders." Molecular Genetics and Metabolism  In: , Vol. 117, No. 1, 01.01.2016, p. 27-32.
  • "Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate." Molecular Genetics and Metabolism Reports  In: , Vol. 5, 01.12.2015, p. 12-14.
  • "Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials." Molecular Genetics and Metabolism  In: , Vol. 116, No. 1-2, 01.09.2015, p. 29-34.
  • "Age-Related Accumulation of Somatic Mitochondrial DNA Mutations in Adult-Derived Human iPSCs." Cell Stem Cell  In: , 01.09.2015.
  • "Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder." Genetics in Medicine  In: , Vol. 17, No. 7, 02.07.2015, p. 561-568.
  • "Erratum : Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder (Genetics in Medicine (2014))." Genetics in Medicine  In: , Vol. 17, No. 5, 08.05.2015, p. 427.
  • "Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders." Molecular Genetics and Metabolism  In: , Vol. 113, No. 1, 01.09.2014, p. 131-135.
  • "A longitudinal study of urea cycle disorders." Molecular Genetics and Metabolism  In: , Vol. 113, No. 1, 01.09.2014, p. 127-130.
  • "Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU)." Journal of Inherited Metabolic Disease  In: , Vol. 37, No. 5, 01.09.2014, p. 735-743.

Additional information

Edit profile